• Home
  • Browse
    • Current Issue
    • By Issue
    • By Author
    • By Subject
    • Author Index
    • Keyword Index
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Peer Review Process
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
 
  • Login
  • Register
Home Articles List Article Information
  • Save Records
  • |
  • Printable Version
  • |
  • Recommend
  • |
  • How to cite Export to
    RIS EndNote BibTeX APA MLA Harvard Vancouver
  • |
  • Share Share
    CiteULike Mendeley Facebook Google LinkedIn Twitter
Journal of the Medical Research Institute
arrow Articles in Press
arrow Current Issue
Journal Archive
Volume Volume 46 (2025)
Volume Volume 45 (2024)
Volume Volume 44 (2023)
Volume Volume 43 (2022)
Volume Volume 42 (2021)
Volume Volume 41 (2020)
Issue Issue 2
Issue Issue 1
Volume Volume 40 (2019)
Volume Volume 39 (2018)
Volume Volume 38 (2017)
Volume Volume 37 (2016)
Volume Volume 36 (2015)
Shalash, M., Badra, M., Imbaby, S., ElBanna, E. (2020). MALONDIALDEHYDE IN TYPE 2 DIABETICS AND ASSOCIATION WITH CARDIOVASCULAR RISK FACTORS. Journal of the Medical Research Institute, 41(2), 21-30. doi: 10.21608/jmalexu.2020.147116
M. Shalash; M. Badra; S. Imbaby; E. ElBanna. "MALONDIALDEHYDE IN TYPE 2 DIABETICS AND ASSOCIATION WITH CARDIOVASCULAR RISK FACTORS". Journal of the Medical Research Institute, 41, 2, 2020, 21-30. doi: 10.21608/jmalexu.2020.147116
Shalash, M., Badra, M., Imbaby, S., ElBanna, E. (2020). 'MALONDIALDEHYDE IN TYPE 2 DIABETICS AND ASSOCIATION WITH CARDIOVASCULAR RISK FACTORS', Journal of the Medical Research Institute, 41(2), pp. 21-30. doi: 10.21608/jmalexu.2020.147116
Shalash, M., Badra, M., Imbaby, S., ElBanna, E. MALONDIALDEHYDE IN TYPE 2 DIABETICS AND ASSOCIATION WITH CARDIOVASCULAR RISK FACTORS. Journal of the Medical Research Institute, 2020; 41(2): 21-30. doi: 10.21608/jmalexu.2020.147116

MALONDIALDEHYDE IN TYPE 2 DIABETICS AND ASSOCIATION WITH CARDIOVASCULAR RISK FACTORS

Article 1, Volume 41, Issue 2, December 2020, Page 21-30  XML PDF (930 K)
Document Type: Original Article
DOI: 10.21608/jmalexu.2020.147116
View on SCiNiTO View on SCiNiTO
Authors
M. Shalash1; M. Badra1; S. Imbaby2; E. ElBanna3
1Department of Internal Medicine , Faculty of Medicine, Alexandria University, Egypt.
2Department of Chemical and Clinical pathology, Faculty of Medicine, Alexandria University, Egypt.
3Department of MBBCH, Alexandria University.
Abstract
Background: Type 2 diabetes mellitus (T2DM) is a progressive chronic
disease with high prevalence all over the world. It is expected to have 693
million people affected by diabetes by 2045. Many body systems are
affected due to complications of DM with major effect on the
cardiovascular system. Dyslipidemia is one of the major risk factors for
cardiovascular disease in diabetes mellitus. Malondialdehyde (MDA) is a
highly toxic end product formed by lipid oxidation that mediates its toxic
effects due to its high reactivity particularly towards proteins and DNA.
Malondialdehyde interacts both irreversibly and reversibly with proteins
and phospholipids causing profound effects, especially in the collagen of
the cardiovascular system. Normally, MDA level remains within normal
values due to antioxidant effects, but in DM these protective effects are
disrupted.
Objective: Measure serum Malondialdehyde level as a marker of lipid
peroxidation in type 2 diabetic patients and its association with other
cardiovascular risk factors.
Patients and methods: The study included 40 diabetic patients recruited
from Outpatient Diabetes Clinic at Alexandria Main University Hospital
in addition to healthy 40 healthy subjects as a control group. Basic data,
clinical examination and laboratory analysis were obtained from all the
subjects within the two groups. Serum Malondialdehyde (MDA) was
measured in the participants within the two groups by using ELISA kit.
Results: The mean serum MDA level was statistically significant higher
in the diabetic cases as compared to the controls (Median MDA was
30.72nmol /ml in cases and 25.16 nmol /ml in the control). There is a
significant increase in serum MDA level with increasing the risk of CV
disease in the whole study subjects and in the diabetic cases. In the cases
group MDA shows positive correlation with all the study parameters
except high density lipoproteins (HDL) where it revealed negative
correlation. BY ROC curve analysis, a cutoff point more than > 26.57 had
62.5% sensitivity, 70% specificity, 66.4 % positive predictive value (PPV)
and 72.5% negative predictive value (NPV).
Conclusion: Malondialdehyde is a non-invasive biomarker that could be
utilized in differentiation of T2DM cases form healthy controls in addition
for identifying the high-risk diabetic patients for cardiovascular disease
(CVD). However, further large-scale studies are recommended to
accurately determine its sensitivity and specificity.
Keywords
Malondialdehyde; lipid peroxidation; oxidative stress; cardiovascular diseases
Statistics
Article View: 431
PDF Download: 1,819
Home | Glossary | News | Aims and Scope | Sitemap
Top Top

Journal Management System. Designed by NotionWave.